Progesterone involvement in breast development and tumorigenesis - As revealed by progesterone receptor "knockout" and "knockin" mouse models

Steroids

Volumn 68, Issue 10-13, 2003, Pages 779-787

  Ismail, Preeti M ^a   Amato, Paula ^a   Soyal, Selma M ^a   DeMayo, Francesco J ^a   Conneely, Orla M ^a   O'Malley, Bert W ^a   Lydon, John P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Development; Mammary gland; Paracrine mechanism; Progesterone receptor knockout; Tumorigenesis

Indexed keywords

BETA GALACTOSIDASE; PROGESTERONE; PROGESTERONE RECEPTOR;

BREAST DEVELOPMENT; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CONFERENCE PAPER; EPITHELIUM CELL; FIRST TRIMESTER PREGNANCY; KNOCKOUT MOUSE; MODEL; MORPHOLOGY; NONHUMAN; PARACRINE SIGNALING; POSTNATAL DEVELOPMENT; PROTEIN EXPRESSION;

EID: 0346996801     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(03)00133-8     Document Type: Conference Paper

References (58)

1. Pike M.C., Spicer D.V. Hormonal contraception and chemoprevention of female cancers. Endocr. Relat. Cancer. 7:2000;73-83.
2. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J. Mammary Gland Biol. Neoplasia. 7:2002;3-15.
3. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis. 21:2000;427-433.
4. Apter D., Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J. Clin. Endocrinol. Metab. 57:1983;82-86.
5. Apter D., Reinila M., Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int. J. Cancer. 44:1989;783-787.
6. Henderson BE, Pike MC, Bernstein L, Ross RK. Breast cancer. In: Schottenfeld D, Fraumeni Jr J, editors. Cancer epidemiology and prevention, 2nd ed. New York: WB Saunders; 1996. p. 1022-39.
7. Trichopoulos D., MacMahon B., Cole P. Menopause and breast cancer. J. Natl. Cancer Inst. 48:1972;605-613.
8. Pike M.C., Ross R.K. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids. 65:2000;659-664.
9. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. New Engl. J. Med. 346:2002;1660-1662.
10. Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 15:1993;48-65.
11. Key T.J. Serum oestradiol and breast cancer risk. Endocr. Relat. Cancer. 6:1999;175-180.
12. Lydon J.P., Sivaraman L., Conneely O.M. A reappraisal of progesterone action in the mammary gland. J. Mammary Gland Biol. Neoplasia. 5:2000;325-338.
13. Goebelsmann U, Mishell D. The menstrual cycle. In: Mishell D, Davajan V, editors. Reproductive endocrinology, infertility and contraception. Philadelphia: FA Davis; 1979. p. 67-89.
14. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 84:1999;4559-4565.
15. Haslam S.Z., Osuch J.R., Raafat A.M., Hofseth L.J. Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J. Mammary Gland Biol. Neoplasia. 7:2002;93-105.
16. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int. J. Cancer. 81:1999;339-344.
17. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92:2000;328-332.
18. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. J. Am. Med. Assoc. 283:2000;485-491.
19. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33.
20. Cardiff R.D. Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc. Res. Tech. 52:2001;224-230.
21. Clarke A.R. Manipulating the germline: its impact on the study of carcinogenesis. Carcinogenesis. 21:2000;435-441.
22. Silberstein G.B. Postnatal mammary gland morphogenesis. Microsc. Res. Tech. 52:2001;155-162.
23. Wagner K.U., Boulanger C.A., Henry M.D., Sgagias M., Hennighausen L., Smith G.H. An adjunct mammary epithelial cell population in parous females: its role in functional adaptation and tissue renewal. Development. 129:2002;1377-1386.
24. Medina D., Sivaraman L., Hilsenbeck S.G., Conneely O., Ginger M., Rosen J.et al. Mechanisms of hormonal prevention of breast cancer. Ann. N.Y. Acad. Sci. 952:2001;23-35.
25. Sivaraman L., Conneely O.M., Medina D., O'Malley B.W. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12379-12384.
26. Ginger M.R., Gonzalez-Rimbau M.F., Gay J.P., Rosen J.M. Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland. Mol. Endocrinol. 15:2001;1993-2009.
27. D'Cruz C.M., Moody S.E., Master S.R., Hartman J.L., Keiper E.A., Imielinski M.B.et al. Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol. Endocrinol. 16:2002;2034-2051.
28. Tsai M.-J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
29. Schrader W.T., O'Malley B.W. Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J. Biol. Chem. 247:1972;51-59.
30. Conneely O.M., Sullivan W.P., Toft D.O., Birnbaumer M., Cook R.G., Maxwell B.L.et al. Molecular cloning of the chicken progesterone receptor. Science. 233:1986;767-770.
31. Jeltsch J.M., Krozowski Z., Quirin-Stricker C., Gronemyer H., Simpson R.J., Garnier J.M.et al. Cloning of the chicken progesterone receptor. Proc. Natl. Acad. Sci. U.S.A. 83:1986;5424-5428.
32. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., McDonnell D.P. Human progesterone receptor A form is a cell and promoter specific repressor of human progesterone receptor B function. Mol. Endocrinol. 7:1993;1244-1255.
33. Tung L., Mohamed M.K., Hoeffler J.P., Takimoto G.S., Horwitz K.B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol. Endocrinol. 7:1993;1256-1265.
34. Sartorius C.A., Tung L., Takimoto G.S., Horwitz K.B. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem. 268:1993;9262-9266.
35. Mulac-Jericevic B., Mullinax R.A., DeMayo F.J., Lydon J.P., Conneely O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 289:2000;1751-1754.
36. Lydon JP, Soyal S, O'Malley BW, Ismail PM. The progesterone receptor knockout mouse: new insights into progesterone action in vivo. In: Matzuk MM, Brown CW, Kumar TR, editors. Transgenics in endocrinology. Totowa, NJ: Humana Press Inc.; 2000. p. 173-204.
37. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery C.A. Jr.et al. Mice lacking progesterone receptors exhibit pleiotropic reproductive abnormalities. Genes Dev. 9:1995;2266-2278.
38. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20:1999;358-417.
39. Brisken C., Park S., Vass T., Lydon J.P., O'Malley B.W., Weinberg R.A. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5076-5081.
40. MacMahon B., Cole P., Lin T.M., Lowe C.R., Mirra A.P., Ravnihar B.et al. Age at first birth and breast cancer risk. Bull. World Health Organ. 43:1970;209-221.
41. Lydon J.P., Ge G., Kittrell F.S., Medina D., O'Malley B.W. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 59:1999;4276-4284.
42. Huseby R.A., Soares M.J., Talamantes F. Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri. Endocrinology. 116:1985;1440-1448.
43. Das R., Vonderhaar B.K. Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neoplasia. 2:1997;29-39.
44. Welsch C.W., Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 37:1977;951-963.
45. Hovey R.C., Trott J.F., Ginsburg E., Goldhar A., Sasaki M.M., Fountain S.J.et al. Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Dev. Dyn. 222:2001;192-205.
46. Ismail P.M., Li J., DeMayo F.J., O'Malley B.W., Lydon J.P. A novel lacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol. Endocrinol. 16:2002;2475-2489.
47. Seagroves T.N., Lydon J.P., Hovey R.C., Vonderhaar B.K., Rosen J.M. C/EBPβ(CCAAT/Enhancer Binding Protein) controls cell fate determination during mammary gland development. Mol. Endocrinol. 14:2000;359-368.
48. Clarke R.B., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57:1997;4987-4991.
49. Russo J., Ao X., Grill C., Russo I.H. Pattern of distribution of cells positive for estrogen receptor-α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53:1999;217-227.
50. Kurita T., Young P., Brody J.R., Lydon J.P., O'Malley B.W., Cunha G.R. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology. 139:1998;4708-4713.
51. Kurita T., Lee K.J., Cooke P.S., Lydon J.P., Cunha G.R. Paracrine regulation of epithelial progesterone receptor and lactoferrin by progesterone in the mouse uterus. Biol. Reprod. 62:1999;831-838.
52. Kurita T., Wang Y.Z., Donjacour A.A., Zhao C., Lydon J.P., O'Malley B.W.et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ. 8:2001;192-200.
53. Bradbury J.M., Edwards P.A.W., Niemeyer C.C., Dale T.C. Wnt-4 expression induces a pregnancy-like growth pattern in reconstituted mammary glands in virgin mice. Dev. Biol. 170:1995;553-563.
54. Brisken C., Heineman A., Chavarria T., Elenbaas B., Tan J., Dey S.K.et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 14:2000;650-654.
55. Fata J.E., Kong Y.Y., Li J., Sasaki T., Irie-Sasaki J., Moorehead R.A.et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 103:2000;41-50.
56. Silberstein G.B., Dressler G.R., Van Horn K. Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene. 21:2002;1009-1016.
57. Sunil N., Bennett J.M., Haslam S.Z. Hepatocyte growth factor is required for progestin-induced epithelial cell proliferation and alveolar-like morphogenesis in serum-free culture of normal mammary epithelial cells. Endocrinology. 143:2002;2953-2960.
58. Soyal S., Ismail P.M., Li J., Mulac-Jericevic B., Conneely O.M., Lydon J.P. Progesterone receptors - animal models and cell signaling in breast cancer: progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics. Breast Cancer Res. 4:2002;191-196.